keyword
MENU ▼
Read by QxMD icon Read
search

Crohns and colitis

keyword
https://www.readbyqxmd.com/read/29451523/-towards-new-therapeutic-paradigms-beyond-symptom-control-in-the-management-of-inflammatory-bowel-diseases
#1
Stefano Festa, Giulia Zerboni, Annalisa Aratari, Riccardo Ballanti, Claudio Papi
Inflammatory bowel diseases, Crohn's disease and ulcerative colitis are chronic relapsing conditions that may result in progressive bowel damage, high risk of complications, surgery and permanent disability. The conventional therapeutic approach for inflammatory bowel diseases is based mainly on symptom control. Unfortunately, a symptom-based therapeutic approach has little impact on major long-term disease outcomes. In other chronic disabling conditions such as diabetes, hypertension and rheumatoid arthritis, the development of new therapeutic approaches has led to better outcomes...
January 2018: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/29448862/filgotinib-for-the-treatment-of-crohn-s-disease
#2
Remi Labetoulle, Stephane Paul, Xavier Roblin
Inflammatory Bowel Diseases, such as Crohn's disease (CD) and Ulcerative Colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence. CD is a chronic, progressive immunologically driven disease, with an evolution characterized by succession of periods of progression and remission. New physiopathological pathways are continuously being discovered, the more we understand about how the disease appears and progresses, the more targets become available for the development of novel therapies...
February 15, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29447146/health-risk-behaviors-and-chronic-conditions-among-adults-with-inflammatory-bowel-disease-united-states-2015-and-2016
#3
Fang Xu, James M Dahlhamer, Emily P Zammitti, Anne G Wheaton, Janet B Croft
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, involves chronic inflammation of the gastrointestinal tract. In 2015, an estimated 3.1 million adults in the United States had ever received a diagnosis of IBD (1). Nationally representative samples of adults with IBD have been unavailable or too small to assess relationships between IBD and other chronic conditions and health-risk behaviors (2). To assess the prevalence of health-risk behaviors and chronic conditions among adults with and without IBD, CDC aggregated survey data from the 2015 and 2016 National Health Interview Survey (NHIS)...
February 16, 2018: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29446764/antibodies-against-glycoprotein-2-display-diagnostic-advantages-over-asca-in-distinguishing-cd-from-intestinal-tuberculosis-and-intestinal-beh%C3%A3-et-s-disease
#4
Shulan Zhang, Jing Luo, Ziyan Wu, Dirk Roggenbuck, Peter Schierack, Dirk Reinhold, Ji Li, Xiaofeng Zeng, Fengchun Zhang, Jiaming Qian, Yongzhe Li
OBJECTIVES: There is an increasing need to identify reliable biomarkers for distinguishing Crohn's disease (CD) from other gastrointestinal disorders sharing similar clinical and pathological features. This study aimed at evaluating the diagnostic potential of antibodies to zymogen granule glycoprotein GP2 (aGP2) in a large, well-defined Chinese cohort with a special focus on their role in discriminating CD from intestinal Behçet's disease (BD) and intestinal tubercolosis (ITB). METHODS: A total of 577 subjects were prospectively enrolled, including 171 patients with CD, 208 patients with ulcerative colitis (UC), 71 with BD, 57 with ITB and 70 healthy controls (HC)...
February 15, 2018: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/29446723/immunomodulatory-effects-of-flavonoids-in-the-prophylaxis-and-treatment-of-inflammatory-bowel-diseases-a-comprehensive-review
#5
Daniela Ribeiro, Carina Proenca, Silvia Rocha, Jose L F C Lima, Felix Carvalho, Eduarda Fernandes, Marisa Freitas
Inflammatory bowel diseases (IBD) comprise two disorders of idiopathic chronic intestinal inflammation that affect about three million people worldwide: Crohn's disease and ulcerative colitis. Nowadays, the first-line of treatment for patients with mild to moderate symptoms of IBD comprises corticosteroids, immunosuppressants, antibiotics, and biological agents. Unfortunately, none of these drugs are curative, and their long-term use may cause severe side effects and complications. Almost 40% of IBD patients use alternative therapies to complement the conventional one, and flavonoids are gaining attention for this purpose...
February 14, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29441457/effect-of-vsl-3-probiotic-in-a-patient-with-glycogen-storage-disease-type-ia-and-irritable-bowel-disease-like-disease
#6
Miguel Carnero-Gregorio, Alberto Molares-Vila, Alberte Corbalán-Rivas, Carlos Villaverde-Taboada, Carmen Rodríguez-Cerdeira
Gut Inflammatory bowel disease (IBD) is a group of chronic gastrointestinal disorders characterised by relapsing and remitting inflammation of the gastrointestinal tract. The two most common types of IBDs are ulcerative colitis and Crohn's disease. Patients with glycogen storage disease (GSD) type Ia present with gastrointestinal symptoms such as recurrent abdominal pain, bloating and changes in stool form or frequency, which is clinically difficult to distinguish from IBD. We report the case of a 36-year-old man with GSD type Ia and IBD-like disease...
February 13, 2018: Probiotics and Antimicrobial Proteins
https://www.readbyqxmd.com/read/29441064/impact-of-cigarette-smoking-on-the-gastrointestinal-tract-inflammation-opposing-effects-in-crohn-s-disease-and-ulcerative-colitis
#7
REVIEW
Loni Berkowitz, Bárbara M Schultz, Geraldyne A Salazar, Catalina Pardo-Roa, Valentina P Sebastián, Manuel M Álvarez-Lobos, Susan M Bueno
Cigarette smoking is a major risk factor for gastrointestinal disorders, such as peptic ulcer, Crohn's disease (CD), and several cancers. The mechanisms proposed to explain the role of smoking in these disorders include mucosal damage, changes in gut irrigation, and impaired mucosal immune response. Paradoxically, cigarette smoking is a protective factor for the development and progression of ulcerative colitis (UC). UC and CD represent the two most important conditions of inflammatory bowel diseases, and share several clinical features...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29440933/population-based-cohort-study-on-comparative-effectiveness-and-safety-of-biologics-in-inflammatory-bowel-disease
#8
Riccardo Di Domenicantonio, Francesco Trotta, Silvia Cascini, Nera Agabiti, Anna Kohn, Antonio Gasbarrini, Marina Davoli, Antonio Addis
Background: The comparison of effectiveness and safety of anti-tumor necrosis factor-alpha agents for the treatment of inflammatory bowel disease (IBD) is relevant for clinical practice and stakeholders. Objective: The objective of this study was to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn's disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). Methods: A retrospective population-based cohort study was performed using health information systems data from Lazio region, Italy...
2018: Clinical Epidemiology
https://www.readbyqxmd.com/read/29439003/impact-of-red-and-processed-meat-and-fibre-intake-on-treatment-outcomes-among-patients-with-chronic-inflammatory-diseases-protocol-for-a-prospective-cohort-study-of-prognostic-factors-and-personalised-medicine
#9
Robin Christensen, Berit L Heitmann, Karina Winther Andersen, Ole Haagen Nielsen, Signe Bek Sørensen, Mohamad Jawhara, Anette Bygum, Lone Hvid, Jakob Grauslund, Jimmi Wied, Henning Glerup, Ulrich Fredberg, Jan Alexander Villadsen, Søren Geill Kjær, Jan Fallingborg, Seyed A G R Moghadd, Torben Knudsen, Jacob Brodersen, Jesper Frøjk, Jens Frederik Dahlerup, Anders Bo Bojesen, Grith Lykke Sorensen, Steffen Thiel, Nils J Færgeman, Ivan Brandslund, Tue Bjerg Bennike, Allan Stensballe, Erik Berg Schmidt, Andre Franke, David Ellinghaus, Philip Rosenstiel, Jeroen Raes, Mette Boye, Lars Werner, Charlotte Lindgaard Nielsen, Heidi Lausten Munk, Anders Bathum Nexøe, Torkell Ellingsen, Uffe Holmskov, Jens Kjeldsen, Vibeke Andersen
INTRODUCTION: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Little is known about the effects of dietary lifestyle as a prognostic factor that may enable personalised medicine...
February 8, 2018: BMJ Open
https://www.readbyqxmd.com/read/29430672/review-article-predictors-of-response-to-vedolizumab-and-ustekinumab-in-inflammatory-bowel-disease
#10
REVIEW
A Barré, J-F Colombel, R Ungaro
BACKGROUND: Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4 β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the armamentarium for IBD increases in coming years, it will become important to understand factors associated with response in order to best position and personalise therapy...
February 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29430323/declining-use-of-combination-infliximab-and-immunomodulator-for-inflammatory-bowel-disease-in-the-community-setting
#11
Joshua C Berkowitz, Joanna Stein-Fishbein, Sundas Khan, Richard Furie, Keith S Sultan
AIM: To describe trends of combination therapy (CT) of infliximab (IFX) and immunomodulator (IMM) for inflammatory bowel disease (IBD) in the community setting. METHODS: A retrospective study was conducted of all IBD patients referred for IFX infusion to our community infusion center between 04/01/01 and 12/31/14. CT was defined as use of IFX with either azathioprine, 6-mercaptopurine, or methotrexate. We analyzed trends of CT usage overall, for Crohn's disease (CD) and ulcerative colitis (UC), and for the subgroups of induction patients...
February 6, 2018: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29429045/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease
#12
REVIEW
Katsuyoshi Matsuoka, Taku Kobayashi, Fumiaki Ueno, Toshiyuki Matsui, Fumihito Hirai, Nagamu Inoue, Jun Kato, Kenji Kobayashi, Kiyonori Kobayashi, Kazutaka Koganei, Reiko Kunisaki, Satoshi Motoya, Masakazu Nagahori, Hiroshi Nakase, Fumio Omata, Masayuki Saruta, Toshiaki Watanabe, Toshiaki Tanaka, Takanori Kanai, Yoshinori Noguchi, Ken-Ichi Takahashi, Kenji Watanabe, Toshifumi Hibi, Yasuo Suzuki, Mamoru Watanabe, Kentaro Sugano, Tooru Shimosegawa
Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn's disease (CD) in Japanese...
February 10, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29426615/low-childhood-high-density-lipoprotein-cholesterol-levels-and-subsequent-risk-for-chronic-inflammatory-bowel-disease
#13
Markku Voutilainen, Nina Hutri-Kähönen, Päivi Tossavainen, Taina Sipponen, Niina Pitkänen, Tomi Laitinen, Eero Jokinen, Tapani Rönnemaa, Jorma S A Viikari, Olli T Raitakari, Markus Juonala
BACKGROUND AND AIMS: Several genetic and environmental risk factors have been linked to chronic inflammatory bowel disease (IBD). The incidence of IBD has significantly increased in developed countries during last decades. The aim of the present study was to examine childhood risk factors for subsequent IBD diagnosis in a longitudinal cohort study of children and adolescents. METHODS: A Finnish study population consisting of 3551 children and adolescents originally evaluated as part of the Cardiovascular Risk in Young Finns study in 1980...
January 31, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29424399/-presence-of-intracellular-escherichia-coli-in-patients-with-inflammatory-bowel-disease
#14
Marjorie De La Fuente, Isidora Chahuán, RocÍo Gutiérrez, David Díaz-Jiménez, Mauricio Olivares, Roberto Vidal, Daniela Simian, Carolina Figueroa, Rodrigo Quera, Marcela A Hermoso
BACKGROUND: Different strains of invasive Escherichia coli (E. coli), isolated from intestinal mucosa of patients, are related to the pathogenesis of inflammatory bowel diseases (IBD). AIM: To evaluate an association between intracellular E. coli and IBD; its clinical characteristics and use of steroids. MATERIAL AND METHODS: Sixty one patients with Crohn's disease and 83 with ulcerative colitis were studied. To determine the intracellular E...
September 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29422814/t-cell-immune-response-against-cytomegalovirus-in-peripheral-blood-and-colonic-mucosa-from-ulcerative-colitis-and-crohn-s-disease-patients
#15
Seung-Joo Nam, Eun Sun Kim, Yoon Tae Jeen
No abstract text is available yet for this article.
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422796/quality-indicators-in-inflammatory-bowel-disease
#16
REVIEW
Sameer K Berry, Gil Y Melmed
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic, debilitating, and expensive condition affecting millions of people globally. There is significant variation in the quality of care for patients with IBD across North America, Europe, and Asia; this variation suggests poor quality of care due to overuse, underuse, or misuse of health services and disparity of outcomes. Several initiatives have been developed to reduce variation in care delivery and improve processes of care, patient outcomes, and reduced healthcare costs...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422795/immunological-pathogenesis-of-inflammatory-bowel-disease
#17
REVIEW
Seung Hoon Lee, Jeong Eun Kwon, Mi-La Cho
Inflammatory bowel disease (IBD) is a chronic inflammatory state of the gastrointestinal tract and can be classified into 2 main clinical phenomena: Crohn's disease (CD) and ulcerative colitis (UC). The pathogenesis of IBD, including CD and UC, involves the presence of pathogenic factors such as abnormal gut microbiota, immune response dysregulation, environmental changes, and gene variants. Although many investigations have tried to identify novel pathogenic factors associated with IBD that are related to environmental, genetic, microbial, and immune response factors, a full understanding of IBD pathogenesis is unclear...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422794/asian-organization-for-crohn-s-and-colitis-and-asia-pacific-association-of-gastroenterology-consensus-on-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-anti-tumor-necrosis-factor-treatment-part-2-management
#18
REVIEW
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422793/asian-organization-for-crohn-s-and-colitis-and-asia-pacific-association-of-gastroenterology-consensus-on-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-anti-tumor-necrosis-factor-treatment-part-1-risk-assessment
#19
REVIEW
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29420705/differential-expression-of-micrornas-in-peripheral-blood-mononuclear-cells-identifies-autophagy-and-tgf-beta-related-signatures-aberrantly-expressed-in-inflammatory-bowel-disease
#20
Aylia Mohammadi, Orlaith B Kelly, Melissa Filice, Boyko Kabakchiev, Michelle I Smith, Mark S Silverberg
Background and Aims: MicroRNAs (miRNAs) have emerged as important regulators in inflammatory bowel disease (IBD). This study investigated differential expression of miRNAs across clinical phenotypes in a well-characterized cohort of IBD patients and healthy controls (HCs). Methods: A cohort with Crohn's disease (CD), ulcerative colitis (UC), and HC was prospectively accrued. Total RNA was extracted from peripheral blood mononuclear cells for all subjects. MiRNA expression was measured using NanoString Technologies...
February 6, 2018: Journal of Crohn's & Colitis
keyword
keyword
16035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"